Immunization Branch
|
 |
|
Licensure of Prevnar 13 will not affect child-care facility requirements
On February 24, 2010, the FDA approved Prevnar 13, a 13-valent pneumococcal conjugate vaccine for children ages 6 weeks through 5 years. The new vaccine protects against the 7 serotypes of the bacterium Streptococcus pneumoniae contained in the current PCV-7 vaccine, plus 6 additional serotypes.
The new 13-valent Prevnar vaccine is intended to replace the current 7-valent vaccine, and children who have received one or more doses of PCV-7 may complete the series with PCV-13.
Will this affect requirements in child-care facilities?
No, this will not affect requirements in child-care facilities. If a child has received either PCV-7 or PCV-13, or a combination of these two, then as long as the child has the required dose(s), this will be considered in compliance.
For additional information, please refer to the FDA’s Approved Products information for Prevnar 13:
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm
MMWR official recommendation for PCV13 - 
36 pages, Morbidity and Mortality Weekly Report, March 12, 2010
Return to School and Child-care Requirements